# RESEARCH ARTICLE (EXPERIMENTAL)



# Characterisation of the inflammatory response in Dupuytren's disease

Christina Mayerl<sup>1,2</sup>, Barbara Del Frari<sup>3</sup>, Walther Parson<sup>4</sup>, Guenther Boeck<sup>1</sup>, Hildegunde Piza-Katzer<sup>3</sup>, Georg Wick<sup>1</sup> & Dolores Wolfram<sup>3</sup>

<sup>1</sup>Laboratory of Autoimmunity, Division of Experimental Pathophysiology and Immunology, Biocenter, Medical University of Innsbruck, Innsbruck, Austria, <sup>2</sup>Department of Internal Medicine III – Cardiology and Angiology, Medical University of Innsbruck, Innsbruck, Austria, <sup>3</sup>Department of Plastic, Reconstructive and Aesthetic Surgery, Medical University of Innsbruck, Innsbruck, Austria, and <sup>4</sup>Institute of Legal Medicine, Medical University of Innsbruck, Innsbruck, Austria

#### Abstract

*Background*: Dupuytren's disease is characterised by fibrotic nodule and cord formation in the palmar aponeurosis. The pathophysiology of the disease is still unknown, although cell stress and subsequent activation of immune mechanisms seems to be crucial. *Materials and methods*: Surgically obtained tissue and blood samples of 100 Dupuytren patients were processed by immunohistochemistry, flow cytometry, as well as immunoscope analysis. Macroscopically normal aponeurotic tissue served as control. *Results*: Locally, microvascular alterations and massive infiltration by mononuclear cells (CD3+, CD4>CD8, CD45RO>CD45RA, S100 protein, CD56, CD68, scarce CD19 and mast cells) forming perivascular clusters were found in DD tissue. Cytokine profiling of fibromatosis tissue-derived T-cells showed a Th1/TH17-weighted immune response. Immunoscope analysis revealed a restricted T-cell receptor  $\alpha/\beta$  repertoire pointing to an (auto)antigen-driven process. *Conclusion*: The striking accumulation of immune cells, expression of leukocyte adhesion molecules, as well as pro-inflammatory and profibrotic cytokines near markedly narrowed vessels supports the theory that the abnormal proliferation of fibroblasts and production of extracellular matrix proteins in DD seems to be related to immune-mediated microvascular damage. The restricted T-cell receptor repertoire of intra-lesional T-cells points to an antigen-driven process. T-cells seem to play an important role in the development of Dupuytren's disease.

Key Words: Palmar fibromatosis, immune cells, inflammation

#### Introduction

Palmar fibromatosis or Dupuytren's disease (DD) is characterised by fibrotic nodule and cord formation with progressive contraction of the palmar fascia resulting in finger flexion deformity. Currently, therapy consists of surgical excision of the abnormal fascia, collagenase injections, or percutaneous needle fasciotomy (PNF), neither of which helps to heal the deformity or prevent frequent recurrence [1,2]. Despite positive family histories,  $\sim 30\%$  of cases are sporadic. Thus, a combination of environmental factors and genetic predisposition seems to underlie the pathogenesis of this condition [3,4]. In particular, damage to and occlusion of the palmar microvasculature are likely to be triggering events [5]. A range of predisposing "stress factors", such as smoking, and high alcohol consumption, on the one hand, and extreme and sustained vibration shock to the hand, on the other, are known to be associated with vascular damage and the development of DD, respectively [6,7]. T-cells play an important role in the induction and perpetuation of various fibrotic conditions [8]. In a recent review on the immunology of fibrosis, we set forth two paradigmatic axioms, namely (a) no fibrosis without prior and concomitant inflammation, and (b) irrespective of the primary disease underlying the development of fibrosis, the final profibrotic molecular pathway is always stereotypical [9]. So far, only a few reports have focused on the initial role of immune cells – especially T-cells – in the development of palmar fibromatosis [10,11]. Baird et al. [12] proposed that the onset of DD following injury in genetically susceptible individuals might be related to the large pool of activated Tcells and macrophages present in the affected palmar aponeurosis. In the context of capsular fibrosis around silicone breast implants, our group has shown that T regulatory and effector cells are main drivers in this fibrotic process [13].

In the present study, DD tissue-infiltrating immune cells were phenotypically characterised and analysed for their potential capability for cytokine production. The microvascular architecture with special focus on adhesion molecules was also investigated. In addition, fibromatosis-derived T-cells were isolated and analysed for signs of clonal expansion in order to support or exclude an antigen-driven process. Although microarray data are already available for DD tissue samples, extensive studies on the protein level are still needed [14]. We analysed the cellular and molecular composition of DD fibromatous tissue, with an extensive panel of antibodies in a great number of patients. Additionally, we tested the hypothesis that a combination of various ''stress factors'' leads to localised activation of the immune system in Dupuytren's patients.

Correspondence: Dolores Wolfram, MD, Assistant Professor, Department of Plastic, Reconstructive and Aesthetic Surgery, Medical University of Innsbruck, Anichstrasse 35, 6020 Innsbruck, Austria. Tel: +43 512 504 82050. Fax: +43 512 504 22735. E-mail: dolores.wolfram@i-med.ac.at

## Materials and methods

#### Subjects and controls

One hundred patients undergoing fasciectomy for DD at the Department of Plastic and Reconstructive Surgery, Innsbruck Medical University, were included in the study (77 men, 23 women; age range = 21-83 years; mean = 60.3; median = 61). Preoperatively, all patients had confirmed diagnosis of DD. Tissue samples from Dupuytren's patients were obtained after partial or complete fasciectomy, these specimens consisted of excised cords and/or nodules, not otherwise needed for routine pathological diagnostics. Peripheral blood from DD patients, as well as macroscopically uncompromised aponeurotic tissue were used for control purposes. Table 1 displays sample numbers, which were included for final data generation. All study participants responded to a questionnaire about current health status and smoking habits. The Ethics Committee of the Medical University Innsbruck gave approval for the study (Study protocol #AN2218), and written informed consent was obtained from all participants. Blood was

Table 1. Overview of used methods and patient samples.

Techniques	Nodule, <i>n</i>	Cord, n	Normal fascia, <i>n</i>	Unspecified Dupuytren tissue*, <i>n</i>
Immunohistochemical analysis	31	37	22	63
Immunoscope analysis FACS analysis Cytokine analysis	15			33 15

\*These tissue samples were not classified from the surgeons into cord or nodule.

collected during general anaesthesia. Standardised preand postoperative pictures were taken from patients' hands (Figure 1).

#### Immunohistochemistry and immunofluorescence

Serial paraffin sections  $(4 \,\mu\text{m})$  of buffered formaldehyde fixed specimens were deparaffinised, subjected to antigen retrieval procedures adjusted for each single antibody-conjugate combination in pilot studies and stained immunohistochemically or by immunofluorescence (see Table 1). The number of slides and stainings, which we analysed per patient, varied due to the availability of different source material. The analysis of more than 3000 slides provided the basis for a semi-quantitative evaluation (Table 2). Appropriate negative controls consisting of either mouse isotype or rabbit immunoglobulin fractions were included in all assays.

#### Isolation and expansion of fibromatosis-derived T-cell lines

Isolation and expansion of lesion-derived T-cells was performed as detailed previously [13]. T-cell lines could be successfully cultured out of tissue samples from 33 patients. Briefly, the palmar fibromatosis cords and nodules were washed, cut into small pieces (ca.  $2 \times 2 \times 2$  mm), and incubated without homogenisation (37°C, 5% CO<sub>2</sub>) in a 6well Petri dish plate in 1640 RPMI supplemented with IL-2 (20 U/ml, kindly provided by Dr E. Liehl, Novartis Research Institute, Vienna, Austria) on days 1 and 3. After 7 days, the T cell-containing supernatant was transferred to flat-bottom 24-well plates, stimulated with OKT3 (10 ng/ml Orthoclone OKT3, Janssen-Cilag, Saunderton, UK), IL-2 (20 U/ml) and autologous, irradiated (30 Gy) peripheral blood mononuclear cells (PBMCs) (5 × 10<sup>5</sup>/ml) as feeder cells. Autologous PBMCs were cultivated in exactly the same way. In 15

Figure 1. (A, B) Preoperative picture of Dupuytren's contracture involving the fifth ray of the left hand. Obvious extension deficit in the PIP joint. (C, D) Postoperative picture after partial fasciectomy.

Table 2.	Overview	on protein	and cell	expression	in I	Dupuytren	s	tissue
----------	----------	------------	----------	------------	------	-----------	---	--------

Adhesian molecules       E-Selectin (CD62P)       activated Ec $\pm 10$ some vascular Ec         E-Selectin (CD62P)       activated Ec $\pm 10$ some vascular Ec         VAP-I       (CD106)       Fc       some vascular Mc         VCAM-1 (CD106)       Fc       some vascular Lis       some vascular Lis         Cytokines and Enzymes       actus phase protein $\pm 10$ $\pm 10$ $\pm 10$ MIR       Main inflande tissues $\pm 10$ $\pm 10$ $\pm 10$ MIR       Main inflande tissues $\pm 10$ $\pm 10$ $\pm 10$ MIR-2       Cytoplasnic $\pm 10$ $\pm 10$ $\pm 10$ $\pm 10$ MIR-2       Cytoplasnic $\pm 10$ </th <th>Antibody</th> <th>Specificity</th> <th>Quantification</th> <th>Dupuytren's tissue expression</th>	Antibody	Specificity	Quantification	Dupuytren's tissue expression
E-Selectin (CD62-E) activated Ec + 10 ++ some vascular Ec Selectin (CD62-E) activated Ec + 11 + 0 ++ some vascular Ec VAR-1 (CD106) Ec + 10 ++ 10 ++ some vascular Ec Some vascular Ec Some vascular Ec Some positive cells focal accumulation of positive cells activated Ec + 10 ++ 10 ++ some vascular Ec Some positive cells located adjacent to vessels in fibrocellular modules Some positive cells in positier at some positive second some some adjacent to vessels Some positive accurate peripheral to modules and in MNC fibroite stage modules and in MNC Some positive cells in proliferative modules and in MNC Some positive cells in proliferative modules and in MNC CD1a De; activ. T-cells + to ++ Some cells located adjacent to vessels CD3 T-cells + to ++ Some cells located adjacent to vessels CD3 T-cells + to ++ Some cells located adjacent to vessels CD3 most LC + CD4 T helper cells + CD5 mature granulocytes + to ++ Some cells located adjacent to vessels CD3 most LC + CD4 H helphoid precursors + to error CD5 most LC + CD5 mature granulocytes + to error CD5 most LC + CD5 mature granulocytes + to error CD5	Adhesion molecules			
Selection (CD02-P)         activated Fig.         ethol         many vacuum Fig.           VAR-D         Ec, SNC         ethol         some vacuum Fig.         some vacuum Fig.           VCAM-1 (CD106)         Ec         + to ++         some positive cells (focal accumulation of positive cells adjacent to vessels adjacent to vessels.           RP         adjacent in filamed tissues + to 1++         some positive vessels and proliferative nodules.           MIE         Ma in acute inflamed tissues + to 1++         some positive cells located adjacent to vessels.           MRP-3         Mo, Ma in acute inflamed tissues + to 1++         some positive cells located adjacent to vessels.           MRP-4         Mo, Ma in acute inflamed tissues + to 1++         some positive cells located adjacent to vessels.           MRP-2         cytoplasmic         + to 1++         reasolut PAC: cells coated adjacent to vessels.           TGF5-1         cytoplasmic         + to 1++         some positive cells in proliferative nodules.           Fieldhelin         Fieldhelin         Fieldhelin         Fieldhelin         Fieldhelin           Stress proteine         Hieldhelin         Fieldhelin         Fieldhelin         Fieldhelin           CD1         Cells         Cells         proliferative nodules and In MNC inflitteric located adjacent to vessels.           Monuclear cells <td< td=""><td>E-Selectin (CD62-E)</td><td>activated Ec</td><td>+ to ++</td><td>some vascular Ec</td></td<>	E-Selectin (CD62-E)	activated Ec	+ to ++	some vascular Ec
NATESE.C. SMCHTsome vascular $Ec$ spectrum (CD106)E.C.HTVCAM-1 (CD106)E.C.+ to ++spectrum (Exp adjacent to vesselssome positive vesls and proliferative nodulesCrokines and Enzymev (CMP)acute phase protein++ to ++spectrum (CMP) positive cells located adjacent to vesselsMIEMa in inflamed tissues+ to ++spectrum (CMP) spectrum (CMP)spectrum (CMP) spectrum (CMP)MRP-8Mo, Ma in acute inflamed tissues+ to ++spectrum (CMP) spectrum (CMP)spectrum (CMP) spectrum (CMP)MRP-1Cytoplasmic+ to ++spectrum (CMP) spectrum (CMP)spectrum (CMP) spectrum (CMP)MRP-2Cytoplasmic+ to ++spectrum (CMP) spectrum (CMP)spectrum (CMP) spectrum (CMP)MMP-2Cytoplasmic+ to ++spectrum (CMP) spectrum (CMP)spectrum (CMP) spectrum (CMP)MMP-2Cytoplasmic+ to ++spectrum (CMP) spectrum (CMP)spectrum (CMP) spectrum (CMP)MMP-2Cytoplasmic+ to ++spectrum (CMP) spectrum (CMP)spectrum (CMP) spectrum (CMP)Monuclear cellsEc+ to ++spectrum (CMP) spectrum (CMP)spectrum (CMP) spectrum (CMP)CD13T-cells+ to ++spectrum (CMP) spectrum (CMP)spectrum (CMP) spectrum (CMP)CD3T-cells+ to ++spectrum (CMP) spectrum (CMP)spectrum (CMP) spectrum (CMP)CD3T-cells+ to ++spectrum (CMP) spectrum (CMP)spectrum (CMP) spectrum (CMP) <tr< td=""><td>P-Selectin (CD62-P)</td><td>activated Ec</td><td>+++</td><td>many vascular Ec</td></tr<>	P-Selectin (CD62-P)	activated Ec	+++	many vascular Ec
VCAM-1 (CD106)E+ to ++sporadic positive cells; focal accumulation of positive cells adjacent to vesselsCytokines and Enzymev CPB LL-17Rexter phase protein exter phase protein exter phase protein exter phase protein the to ++some positive cells coated adjacent to vessels in fibrocellular nodales some positive cells located adjacent to vessels some positive cells located adjacent to vessels some positive cells located adjacent to vessels modulasMRP-8 MRP-14Mo, Ma in acute inflamed tissues + to ++sporadic positive cells located adjacent to vessels some positive cells located adjacent to vessels modulasMRP-12 Cytoplasmic Chife-14eytoplasmic the +to ++Endothelin Sporadic positive cells in proliferative nodules and in MNC infitrate; located near vesselsEndothelin Sporadic positive cellsexternal vesselSporadic positive cellsmodules and instruction to vessels, postive cells in proliferative nodules and in MNC infitrati; located near vesselsSporadic positive cellsmodules and in MNC infitrati; located near vesselsSporadic positive cellspositive cells in proliferative nodules and in MNC infitrati; located near vesselsCD3T-cells+ to ++CD4T helper cells+ to ++CD5exter proteinsCD5most Lc+ to ++CD5activated T/B-cells+ to ++CD5nost Lc+ to ++CD5nost Lc+ to ++CD5nature granulocytes+ to ++CD5natured Fibrocells+ to ++CD55 <td>VAP-1</td> <td>Ec. SMC</td> <td>+++</td> <td>some vascular Ec</td>	VAP-1	Ec. SMC	+++	some vascular Ec
Constance and Enzymes     adjacent to vessels     adjacent to vessels     adjacent to vessels       CPD     acute phase protein     ++ to ++       MIP     Ma in inflamed tissues     + to ++       MRP-1     Mo, Ma in acute inflamed tissues     + to ++       MRP-2     cytoplasmic     + to ++       MRP-2     cytoplasmic     + to ++       MRP-2     cytoplasmic     + to ++       TGF/3-1     cytoplasmic     + to ++       TGF/3-1     cytoplasmic     + to ++       Endothelin     Ec     +++       Endothelin     Ec     +++       Cytoplasmic     + to ++     some positive verils located adjacent to vessels       TGF/3-1     cytoplasmic     + to ++       Suboolitin     cytotoxic T-cells     + to ++	VCAM-1 (CD106)	Ec	+ to ++	sporadic positive cells: focal accumulation of positive cells
Cynokines and Enzymescut phase protein $\pm + t_0$ $\pm + t_0$ some positive vessels and proliferative nodulesLL-17Rcytoplasmic $\pm$ $\pm$ positive cells located adjacent to vessels in fibrocellularMRP-8Mo, Ma in acute inflamed tissues $\pm$ to $\pm \pm$ some positive cells located adjacent to vesselsMRP-2cytoplasmic $\pm$ to $\pm \pm$ some positive cells located adjacent to vesselsMRP-2cytoplasmic $\pm$ to $\pm \pm$ some positive cells located adjacent to vesselsMRP-2cytoplasmic $\pm$ to $\pm \pm$ DidahelinEc $\pm \pm$ some positive cells located adjacent to vesselsIndohelinEc $\pm \pm$ some positive cells in proliferative nodules and in MRCColulative Stress proteinsHSP60, cytoplasmic $\pm \pm$ some positive cells in proliferative nodules and in MRCIndohelinEc $\pm \pm$ some positive cells in proliferative nodules and in MRCIndohelinEc $\pm \pm$ some positive cells in proliferative nodules and in MRCIndohelinEc $\pm \pm$ some positive cells in proliferative nodules and in MRCIndohelinEc $\pm \pm$ some cells in proliferative nodules and in MRCIndohelinEc $\pm \pm$ some cells located adjacent to vesselsCollaDe; activ. T-cells $\pm$ to $\pm \pm$ CollaDe; activ. T-cells $\pm$ some cells located adjacent to vesselsCD1most Lc $\pm$ some cells located adjacent to vesselsCD1most Lc $\pm$ some cells located adjacent to v			1 10 11	adjacent to vessels
Ck0     acute phase protein     ++     some positive vessels and protein tradius modules       L1/R     cytoplasmic     +       MIP     Ma in inflamed tissues     + to ++       MRP-8     Mo. Ma in acute inflamed tissues     + to ++       MRP-1     Mo. Ma in acute inflamed tissues     + to ++       MRP-2     cytoplasmic     + to ++       MIP-2     cytoplasmic     + to ++       TGF/2-1     cytoplasmic     + to ++       Cytoplasmic     + to ++     some positive cells located adjacent to vessels       TGF/2-1     cytoplasmic     + to ++       Cytoplasmic     + to ++     some positive vesues       TGF/2-1     cytoplasmic     + to +++       Someonill     Eddothelin     Ec       Ec     +++     some positive vesues     some positive cells in proliferative modules and in MNC infitures.       Cuidative Stress proteins     ++     some positive cells in proliferative modules and MNC clusters.       Monnuclear cells     nuclear     ++     sporadic positive cells in proliferative modules and MNC clusters.       Monnuclear cells     +     ++     sporadic positive cells in proliferative modules and in MNC infitures.       CD3     T-cells     + to ++     sporadic positive cells in contentially located adjacent to vessels.       CD4     Thelper cells <td>Cytokines and Enzymes</td> <td></td> <td></td> <td></td>	Cytokines and Enzymes			
LL 17R       cytoplasmic       +         MRP       Main inflamed tissues       + to ++       positive cells located adjacent to vessels in fibrocellular notulaes         MRP-8       Mo, Ma in acute inflamed tissues       + to ++       positive cells located adjacent to vessels         MRP-1       cytoplasmic       + to ++       positive cells located adjacent to vessels         MMP-2       cytoplasmic       + to ++       positive cells located adjacent to vessels         TDF/-1       cytoplasmic       + to ++       many positive cells located adjacent to vessels         Smorotolin       cytoplasmic       + to ++       mone positive vessels         Smorotolin       cytoplasmic       + to ++       some positive vessels         Smorotolin       cytoplasmic       + to ++       some positive vessels         Monouclear cells       Dc; activ, T-cells       + to ++       some positive cells preferentially located adjacent to vessels         CD1a       Dc; activ, T-cells       + to ++       sporadic positive cells located adjacent to vessels         CD15       matter granulocytes       + to ++       sporadic positive cells located adjacent to vessels         CD15       matter granulocytes       + to ++       sporadic positive cells located adjacent to vessels         CD16       mots Lc       + to ++	CRP	acute phase protein	++ to <mark>+++</mark>	some positive vessels and proliferative nodules
NHEMa in inflamed tissues+ 10 +++positive cells located adjacent to vesselsMRP-8Mo, Ma in acute inflamed tissues ++ to ++sporadic positive cells located adjacent to vesselsMRP-1Mo, Ma in acute inflamed tissues ++ to +++sporadic positive cells located adjacent to vesselsMMP-2cytoplasmic++ to +++TGF.3-1cytoplasmic++ +TGF.3-1cytoplasmic++ +EndothelinEc+++EndothelinEc+++Stress proteins++Hsp60ruclear++ +Smootidincytoplasmic+++Stress proteins++Hsp60nuclear+++Stress proteins+++Hsp60	IL-17/R	cytoplasmic	+	
MRP-8     Mo, Ma in acute inflamed tissues + to ++     sporadic positive cells located adjacent to vessels       MMP-2     cytoplasmic     + to ++       TGF/-1     cytoplasmic     + to ++       TGF/-1     cytoplasmic     + to ++       Endothelin     Ec     +++       Cytoplasmic     + to ++       Synowialin     cytoplasmic     + to ++       Cytoplasmic     + to ++       Synowialin     cytoplasmic     ++       Momouclear cells     nuclear     +++       Manonuclear cells     nuclear     +++       CD1a     Dc; activ. T-cells     + to ++       CD1a     Dc; activ. T-cells     + to ++       CD1A     T-cells     + to ++       CD1A     T-cells     + to ++       CD1A     T belper cells     + to ++       CD1A     all Lc     ++       CD1B     mattre granulocytes     ++	MIF	Ma in inflamed tissues	+ to <mark>+++</mark>	positive cells located adjacent to vessels in fibrocellular nodules
MRP-14Mo, Ma in acute inflamed tissues ++ to +++some positive cells located adjacent to vessels in fibrocellular and fibroit stageMMP-2cytoplasmic+ to ++map positive acal paripheral to nodules; vessel lumina weakly positive pericytes around vessels and myofbroblasts in profiterative nodulesTNF $\alpha$ Ma+weakly positive cells located adjacent to vesselsEndothelinEc+++some positive cells in profiferative nodules; 	MRP-8	Mo, Ma in acute inflamed tissues	+ to ++	sporadic positive cells located adjacent to vessels
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	MRP-14	Mo, Ma in acute inflamed tissues	++ to <mark>+++</mark>	some positive cells located adjacent to vessels in fibrocellular and fibrotic stage
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	MMP-2	cytoplasmic	+ to ++	vascular SMC; cells located adjacent to vessels
TNF $\alpha$ Ma       +       weakly positive percipts around vessels and myofibroblasts in proliferative nodules         Endothelin       Ec       +++       some positive vascular Ec         Strownion       cytoplasmic       +to +++       some positive cells in proliferative nodules and in MNC infiltrate: located near vessels         Mononuclear cells       nuclear       +++       some positive cells in proliferative nodules and MNC clusters         Mononuclear cells       Dc; activ. T-cells       + to ++       sporadic positive cells preferentially located adjacent to vessels         CD4       T helper cells       + to ++       sporadic positive cells located adjacent to vessels         CD8       cytorixic T-cells       + to ++       sporadic positive cells located adjacent to vessels         CD1a       all Lc       + to ++       sporadic positive cells located adjacent to vessels         CD1a       all Lc       + to ++       sporadic positive cells located adjacent to vessels         CD1a       all Lc       + to ++       sporadic positive cells located adjacent to vessels         CD1a       mature granulocytes       + to ++       sporadic positive cells located in proliferative nodules and adjacent to vessels         CD19       B-cells       + to ++       some cells located in proliferative nodules and adjacent to vessels         CD29       mos	$TGF\beta-1$	cytoplasmic	++	many positive areas peripheral to nodules; vessel lumina
EndothelinEc+++some positive vascular EcSpowiolincytoplasmic+ to +++interstitial tissue and Ec in small vessels(Oxidative) Stress proteinsHSP60, cytoplasmic++some positive cells in proliferative nodules and in MNC(Manonuclear cellsnuclear++mmt positive cells in proliferative nodules and MNC clustersMononuclear cellsDc; activ. T-cells+ to ++sporadic positive cells preferentially located adjacent to vesselsCD3T-cells+ to ++sporadic positive cells located adjacent to vesselsCD4T helper cells+ to ++sporadic positive cells located adjacent to vesselsCD1aall Lc++sporadic positive cells located adjacent to vesselsCD15mature granulocytes+ to ++sporadic positive cells located in proliferative nodules and adjacent to vesselsCD29most Lc+ to ++sporadic positive cells located in proliferative nodulesCD29most Lc+ to ++some cells located in proliferative nodulesCD34B lymphoid precursors+ to ++some cell clusters located adjacent to vesselsCD34B lymphoid precursors+ to ++some cell clusters located adjacent to vesselsCD34B lymphoid precursors+ to ++some cell slocated in proliferative nodules <td><math>TNF\alpha</math></td> <td>Ma</td> <td>+</td> <td>weakly positive pericytes around vessels and myofibroblasts in proliferative nodules</td>	$TNF\alpha$	Ma	+	weakly positive pericytes around vessels and myofibroblasts in proliferative nodules
Synovial (Oxidative) Stress proteinscytoplasmic $\pm$ to $\frac{++}{++}$ intersitial tissue and Ec in small vessels(Oxidative) Stress proteinsHSP60, cytoplasmic $\pm$ some positive cells in proliferative nodules and MNC infiltrate; located mare vesselsImage: Stress proteinsnuclear $\pm$ some positive cells in proliferative nodules and MNC clustersMononiclear cellsDc; activ. T-cells $\pm$ to $\pm$ sporadic positive cells preferentially located adjacent to vesselsCD3T-cells $\pm$ to $\pm$ sporadic positive cells located adjacent to vesselsCD4T helper cells $\pm$ to $\pm$ sporadic positive cells located adjacent to vesselsCD5mature granulocytes $\pm$ to $\pm$ sporadic positive cells located adjacent to vesselsCD1aall Lc $\pm$ sporadic positive cells located adjacent to vesselsCD15mature granulocytes $\pm$ to $\pm$ some cells located in proliferative nodules and adjacent toCD19B-cells $\pm$ to $\pm$ sporadic positive cells located in proliferative nodules and adjacent toCD25activated T/B-cells $\pm$ some cell slocated in proliferative nodulesCD41hyluronan receptor $\pm$ some cell slocated adjacent to vesselsCD43B lymphoid precursors $\pm$ some cell slocated adjacent to vesselsCD44b lyluronan receptor $\pm$ some cell slocated adjacent to vesselsCD45all Ly $\pm$ some cell slocated adjacent to vesselsCD46natural killer cells $\pm$ some cell slocated adjacent to vesselsC	Endothelin	Ec	+++	some positive vascular Ec
OptimizerOptimizerObjectHSP60, cytoplasmic++some positive cells in proliferative nodules and in MNC infilirate; located near vesselsTrac2nuclear++some positive cells in proliferative nodules and MNC clusters vesselsCD1aDc; activ. T-cells+ to ++sporadic positive cells in proliferative nodules and MNC clusters vesselsCD3T-cells+ to ++sporadic positive cells in proliferative nodules and adjacent to vessels sporadic to view cells located adjacent to vessels, sporadic positive cells located adjacent to vesselsCD4T helper cells+ to ++sporadic positive cells located adjacent to vessels, sporadic positive cells located adjacent to vesselsCD1aall Le+ +sporadic positive cells located adjacent to vesselsCD15mature granulocytes+ to ++sporadic positive cells located adjacent to vesselsCD18most Lc+ to ++sporadic positive cells located in proliferative nodules and adjacent to vesselsCD19B-cells+ to ++sporadic positive cells located in proliferative nodulesCD34B lymphoid precursors+ to ++some cells located adjacent to vesselsCD354Activated T/B-cells+ to ++some cells located adjacent to vesselsCD450attuat killer cells+ to ++some cells located adjacent to vesselsCD34B lymphoid precursors+ to ++some cells located adjacent to vesselsCD34B lymphoid precursors+ to ++some cells located adjacent to vesselsCD36 <td>Synoviolin</td> <td>cytoplasmic</td> <td>+ to +++</td> <td>interstitial tissue and Ec in small vessels</td>	Synoviolin	cytoplasmic	+ to +++	interstitial tissue and Ec in small vessels
Hsp60HSP60, cytoplasmic++some positive cells in proliferative nodules and in MNC infiltrate; located near vesselsTm2nuclear++some positive cells in proliferative nodules and MNC clustersMononuclear cellsDc; activ. T.cells+ to ++sporadic positive cells preferentially located adjacent to vesselsCD3T-cells+ to ++sporadic positive cells located adjacent to vesselsCD4T helper cells+ to ++sporadic positive cells located adjacent to vesselsCD8cytotxic T-cells+sporadic positive cells located adjacent to vesselsCD1aall Le++sporadic positive cells located adjacent to vesselsCD15mature granulocytes+ to ++some cells located in proliferative nodules and adjacent to vesselsCD18most Lc+ to ++sporadic positive cells located in proliferative nodules and adjacent to vesselsCD29most Lc+ to ++sporadic positive cells located in proliferative nodulesCD29most Lc+ to ++sporadic costed adjacent to vesselsCD34B lymphoid precursors+ to ++some cell clusters located adjacent to vesselsCD47Lc, Ec, fibroblasts+ to ++some cells located adjacent to vesselsCD49all Ly+ to ++some cells located adjacent to vesselsCD47Lc, Ec, fibroblasts+ to ++some cells located adjacent to vesselsCD48MaActivated Ec, Mo, Ly+ to ++some cells located adjacent to vesselsCD56natural killer cells+ to ++some	(Oxidative) Stress proteins	ejtephenine		
Fra-2 Mononclear cellsnuclear+++many positive cells in proliferative nodules and MNC clustersCD1aDc; activ. T-cells+ to ++sporadic positive cells preferentially located adjacent to vesselsCD3T-cells+ to ++sporadic to view cells located adjacent to vessels; sporadic cellCD4T helper cells+ to ++sporadic positive cells located adjacent to vesselsCD8cytotoxic T-cells+sporadic positive cells located adjacent to vesselsCD1aall Lc++sporadic positive cells located adjacent to vesselsCD15mature granulocytes+ to ++some cells located in proliferative nodules and adjacent to vesselsCD18most Lc+ to ++some cells located in proliferative nodules and adjacent to vesselsCD19B-cells+ to ++sporadic positive cells located in proliferative nodules and adjacent to vesselsCD29most Lc+ to ++sporadic positive cells located in proliferative nodulesCD34B lymphoid precursors+ to +++some cell clusters located adjacent to vesselsCD41Lc Ec, fibrollasts+ to +++some cell clusters located adjacent to vesselsCD43B lymphoid precursors+ to +++some cell clusters located adjacent to vesselsCD44Activated T-cells+++some cell clusters located adjacent to vesselsCD45Activated C-clls+++some cell clusters located adjacent to vesselsCD45Activated Ec, Mo, Ly+++some cell clusteral adjacent to vesselsCD45Activated Ec, Mo, L	Hsp60	HSP60, cytoplasmic	++	some positive cells in proliferative nodules and in MNC infiltrate: located near vessels
Mononuclear cellsDetMathematical control of the positive cells preferentially located adjacent to resselsCD1aDc; activ. T-cells+ to ++sporadic positive cells preferentially located adjacent to vesselsCD3T-cells+ to ++sporadic to view cells located adjacent to vesselsCD4T helper cells+ to ++sporadic to view cells located adjacent to vesselsCD8cytotoxic T-cells+sporadic positive cells located adjacent to vesselsCD11aall Lc++sporadic positive cells located adjacent to vesselsCD15mature granulocytes+ to ++some cells located adjacent to vesselsCD18most Lc+ to ++some cells located adjacent to vesselsCD19B-cells+ to ++sporadic positive cells located in proliferative nodules and adjacent to vesselsCD25activated T/B-cells+ to ++sporadic positive cells located adjacent to vesselsCD44hyaluronan receptor+ to ++sporadic colls located adjacent to vesselsCD45RAanive T-cells++some cell clusters located adjacent to vesselsCD44hyaluronan receptor+ to ++sporadic colls located adjacent to vesselsCD56natural killer cells++sporadic colls located adjacent to vesselsCD56matural killer cells++sporadic colls located adjacent to vesselsCD74B-cells++to ++Sporadic colls located adjacent to vesselssporadic colls located adjacent to vesselsCD44hyaluronan receptor++C	Fra-2	nuclear	+++	many positive cells in proliferative nodules and MNC clusters
CD1aDc; activ. T-cells+ to ++sporadic positive cells preferentially located adjacent to vesselsCD3T-cells+ to ++cell clusters preferentially located adjacent to vessels; sporadic to vew cells located adjacent to vessels; sporadic positive cells located adjacent to vessels clustersCD8cytotoxic T-cells+sporadic positive cells located adjacent to vessels adjacent to vesselsCD8cytotoxic T-cells+sporadic positive cells located adjacent to vessels adjacent to vesselsCD11aall Lc++sporadic positive cells located adjacent to vesselsCD15mature granulocytes+ to ++CD18most Lc+ to ++CD19B-cells+ to ++CD25activated T/B-cells+ to ++some cells located in proliferative nodules adjacent to vesselsCD29most LcffffCD43B lymphoid precursors++ to ffffCD43Activated T-cells++some cell clusters located adjacent to vesselsCD43activated T-cells++some cell clusters located adjacent to vesselsCD43Activated Ec, Mo, Ly++ to ffffCD44B-cells++cD45many positive cells located adjacent to vesselsCD46many positive vascular Ecs and cells located in proliferative nodules; vascular EcsCD47Lc, Ec, Fibroblasts+ to fffCD44B-cells++CD55natural killer cells++CD56matural killer cells++CD7	Mononuclear cells			
CD3T-cells+ to ++cell clusters preferentially located adjacent to vesselsCD4T helper cells+ to ++sporadic to view cells located adjacent to vessels; sporadic cellCD8cytotoxic T-cells+sporadic positive cells located adjacent to vesselsCD11aall Lc++sporadic positive cells located adjacent to vesselsCD15mature granulocytes+ to ++some cells located adjacent to vesselsCD18most Lc++ to ++some cells located adjacent to vesselsCD19B-cells+ to ++cells preferentially located adjacent to vesselsCD29most Lc+++many positive cells located in proliferative nodulesCD34B lymphoid precursors++ to +++some cell slocated adjacent to vesselsCD44hyaluronan receptor+ to +++some cell clusters located adjacent to vesselsCD45RAnaive T-cells+++some cell clusters located adjacent to vesselsCD45RAnaive T-cells++some cell clusters located adjacent to vesselsCD47Lc, E, fibroblasts+ to +++some cells located adjacent to vesselsCD49all Ly++ to +++some cells located adjacent to vesselsCD56natural killer cells++many positive cells located adjacent to vesselsCD56natural killer cells++sporadic cositive cells located in proliferative nodulesCD56natural killer cells++sporadic to some cells located in proliferative nodulesCD56natural killer cells++sporadic to	CD1a	Dc; activ. T-cells	+ to ++	sporadic positive cells preferentially located adjacent to vessels
CD3Thelper cellsHoHoControl control of the	CD3	T-cells	+ to $++$	cell clusters preferentially located adjacent to vessels
CD8cytotxic T-cells+sporadic positive cells located adjacent to vesselsCD11aall Lc++sporadic positive cells located adjacent to vesselsCD15mature granulocytes+ to ++some cells located adjacent to vessels and in proliferativeCD18most Lc+ to ++some cells located in proliferative nodules and adjacent toCD19B-cells+ to ++cells preferentially located adjacent to vesselsCD29most Lc+++many positive cells located in proliferative nodulesCD29most Lc+++many positive cells located adjacent to vesselsCD44blymphoid precursors++ to +++some cell clusters located adjacent to vesselsCD44hyaluroan receptor++ to +++some cell clusters located adjacent to vesselsCD45RAactivated T-cells++some cell clusters located adjacent to vesselsCD41Lc, Ec, Fibroblasts++some cells located adjacent to vesselsCD43all Ly++ to +++some cells located adjacent to vesselsCD44hyaluroan setters++some cells located adjacent to vesselsCD45activated Ec, Mo, Ly++to +++Some cells located adjacent to vesselssome cells located adjacent to vesselsCD44B-cells++some cells located adjacent to vesselsCD47Lc, Ec, Fibroblasts++some cells located adjacent to vesselsCD49all Ly++to +++Some cells located adjacent to vesselssome cells located adjacent to vessels	CD4	T helper cells	+ to ++	sporadic to view cells located adjacent to vessels; sporadic cell clusters
CD3Cplother PeriodPeriodSporadic positive cells located adjacent to vesselsCD11aall Lc++sporadic positive cells located adjacent to vesselsCD15mature granulocytes+ to ++some cells located adjacent to vesselsCD18most Lc+ to ++some cells located adjacent to vesselsCD25activated T/B-cells+ to ++cells preferentially located adjacent to vesselsCD29most Lc+++sporadic positive cells located in proliferative nodulesCD34B lymphoid precursors++ to +++some cell custers located adjacent to vesselsCD44hyaluronan receptor+ to +++some cell custers located adjacent to vesselsCD47Lc, Ec, fibroblasts+ to +++some cells located adjacent to vesselsCD47Lc, Ec, fibroblasts+ to +++some cells located adjacent to vesselsCD56natural killer cells+++some cells located adjacent to vesselsCD56natural killer cells++many positive cells located adjacent to vesselsCD74B-cells++some cells located adjacent to vesselsCD79bB-cells++sporadic to some cells located	CD8	cytotoxic T-cells	+	sporadic positive cells located adjacent to vessels
CD11and ECthe source cells located adjacent to vessels and in proliferative nodulesCD15mature granulocytes+ to ++some cells located adjacent to vessels and in proliferative nodulesCD18most Lc+ to ++some cells located adjacent to vesselsCD19B-cells+ to ++cells preferentially located adjacent to vesselsCD25activated T/B-cells+ to ++sporadic positive cells located in proliferative nodulesCD34B lymphoid precursors+ to +++some cell clusters located adjacent to vesselsCD44hyaluronan receptor+ to +++cells in proliferative nodules and located adjacent to vesselsCD44collstras+ to +++some cell clusters located adjacent to vesselsCD44collstras- cells++CD47Lc, Ec, fibroblasts+ to +++SD66natural killer cells++CD54Activated Ec, Mo, Ly++ to +++SD66natural killer cells++CD56natural killer cells++CD74B-cells++CD74B-cells++SD774B-cells++SD774B-cells++SD774B-cells++SD774B-cells++SD774B-cells++SD774B-cells++SD774B-cells++SD774B-cells++SD774B-cells++SD774B-cells++SD774B-cells++SD774<	CD11a	all I c	, ++	sporadic positive cells located adjacent to vessels
CD13Initial granulocytes+ to ++Some cells located adjacent to vessels and in proincurve nodulesCD18most Lc+ to ++some cells located in proliferative nodules and adjacent to vesselsCD29most Lc+ to ++sporadic positive cells located in proliferative nodulesCD34B lymphoid precursors+ to +++sporadic positive cells located adjacent to vesselsCD45RAnaive T-cells+ to +++vascular EcsCD45ROactivated T-cells+ to +++some cell clusters located adjacent to vesselsCD45ROactivated T-cells+ to +++some cell clusters located adjacent to vesselsCD47Lc, Ec, fibroblats+ to +++some cell clusters located adjacent to vesselsCD47Lc, Ec, fibroblats+ to +++some positive vascular Ecs and cells located in proliferative nodulesCD56natural killer cells+ to +++some cells located adjacent to vesselsCD74B-cells+ to +++sporadic to some cells located adjacent to vesselsCD74B-cells+ to +++sporadic to some cells located adjacent to vesselsCD74B-cells+ to +++sporadic positive cells in proliferative nodulesCD74B-cells+ to +++sporadic to some positive cells located adjacent to vesselsCD74B-cells+ to +++sporadic to some cells located adjacent to vesselsCD74B-cells+ to +++sporadic to some cells located in proliferative nodulesCD74B-cells+ to +++sporadic coslic positive cells located adjacent t	CD15	mature granulocytes		some cells located adjacent to vessels and in proliferative
CD18most Lc+ to ++some cells located in proliferative nodules and adjacent to vesselsCD19B-cells+ to ++cells preferentially located adjacent to vesselsCD25activated T/B-cells+ to ++sporadic positive cells located in proliferative nodules and adjacent to vesselsCD29most Lc+++many positive cells located in proliferative nodulesCD34B lymphoid precursors++ to +++vascular EcsCD44hyaluronan receptor+ to +++cells in proliferative nodules and located adjacent to vesselsCD45RAnaive T-cells++some cell clusters located adjacent to vesselsCD47Lc, Ec, fibroblats++some cells located adjacent to vesselsCD49all Ly++ to +++some cells located adjacent to vesselsCD56natural killer cells++many positive cells located adjacent to vesselsCD56natural killer cells++many positive cells located adjacent to vesselsCD79bB-cells+ to ++sporadic to some cells located adjacent to vesselsCD79bB-cells+ to ++sporadic positive cells located in proliferative nodulesCD79bB-cells+ to ++sporadic positive cells located adjacent to vesselsCD79bB-cells+ to ++sporadic costace adjacent to vesselsCD79bB-cells+ to ++sporadic costace adjacent to vesselsMasteell-Tryptasemast cells++S100Dc++CD26+++some cells located adjacent to vessels </td <td>CD15</td> <td>mature granulocytes</td> <td>T 10 TT</td> <td>nodules</td>	CD15	mature granulocytes	T 10 TT	nodules
CD19B-cells+ to ++cells preferentially located adjacent to vesselsCD29most Lc+++cells preferentially located adjacent to vesselsCD29most Lc+++sopradic positive cells located in proliferative nodulesCD34B lymphoid precursors++ to +++vascular EcsCD44hyaluronan receptor+ to +++cells in proliferative nodules and located adjacent to vesselsCD45RAnaive T-cells++some cell clusters located adjacent to vesselsCD47Lc, Ec, fibroblasts+ to +++some cell clusters located adjacent to vesselsCD49all Ly++ to +++some cells located adjacent to vesselsCD54Activated Ec, Mo, Ly++ to +++some cells located adjacent to vesselsCD56natural killer cells++some cells located adjacent to vesselsCD74B-cells++some cells located adjacent to vesselsCD79bB-cells+ to ++sporadic cosine cells located adjacent to vesselsCD79bB-cells+ to ++sporadic positive cells located adjacent to vesselsCD79bB-cells+ to ++sporadic positive cells located adjacent to vesselsMastcell-Tryptasemast cells++sporadic cosine cells located adjacent to vesselsS100Dc++to ++sporadic cells located in proliferative nodulesTCR $\alpha$ T cells++to ++S100Dc++sporadic cells located adjacent to vesselsS100Dc++some cells located adjacent to vess	CD18	most I c	± to ±±	some cells located in proliferative nodules and adjacent to
CD19B-cells+ to ++cells preferentially located adjacent to vesselsCD25activated T/B-cells+ to ++sporadic positive cells located in proliferative nodules and adjacent to vesselsCD29most Lc+++many positive cells located in proliferative nodulesCD34B lymphoid precursors++ to +++vascular EcsCD440hyaluronan receptor+ to +++some cell clusters located adjacent to vesselsCD45RAactivated T-cells++some cell clusters located adjacent to vesselsCD47Lc, Ec, fibroblasts+ to +++sporadic cells located adjacent to vesselsCD49dall Ly++ to +++some cells located adjacent to vesselsCD47Lc, Ec, fibroblasts+ to +++some cells located adjacent to vesselsCD49dall Ly++ to +++some cells located adjacent to vesselsCD56natural killer cells++some cells located adjacent to vesselsCD68Ma+ to +++sporadic to some cells located adjacent to vesselsCD74B-cells+ to +++some cells located adjacent to vesselsCD79bB-cells+ to +++sporadic to some positive cells located adjacent to vesselsHLA-DP, DQ, DRantigen presenting cells+++sporadic to some positive cells located adjacent to vesselsS100Dc+++sporadic cells located between fat cells and vessels; many Ruffini bodiesTCR $\gamma/\delta$ T cells+++TCR $\gamma/\delta$ T cells+TCR $\gamma/\delta$ T cells+<	CD18	most Le	+ 10 ++	vessels
CD25activated T/B-cells+ to ++sporadic positive cells located in proliferative nodules and adjacent to vesselsCD29most Lc++to +++many positive cells located in proliferative nodulesCD34B lymphoid precursors++ to +++vascular EcsCD44hyaluronan receptor+ to +++some cell clusters located adjacent to vesselsCD45RAnaive T-cells++some cell clusters located adjacent to vesselsCD47Lc, Ec, fibroblasts+ to +++some cell slocated adjacent to vesselsCD54Activated Ec, Mo, Ly++ to +++some cells located adjacent to vesselsCD56natural killer cells++many positive cells in proliferative nodules; Ruffine bodies;CD74B-cells++ to +++some cells located adjacent to vesselsCD56natural killer cells++many positive cells located adjacent to vesselsCD74B-cells++ to +++some cells located adjacent to vesselsCD74B-cells++ to +++some cells located adjacent to vesselsCD74B-cells++ to +++sporadic to some cells located in proliferative nodulesCD79B-cells++ to +++sporadic to some positive cells located in proliferative nodulesCD79bB-cells++ to +++sporadic cells located in proliferative nodulesMastcell-Tryptasemast cells++ to +++S100Dc+++TCR $\alpha$ T cells++TCR $\gamma/\delta$ T cells++ to +++TCR $\gamma/\delta$ T cells++ to +++ <td>CD19</td> <td>B-cells</td> <td>+ to ++</td> <td>cells preferentially located adjacent to vessels</td>	CD19	B-cells	+ to ++	cells preferentially located adjacent to vessels
CD29most Lc+++many positive cells located in proliferative nodulesCD34B lymphoid precursors++ to +++vascular EcsCD44hyaluronan receptor+ to +++cells in proliferative nodules and located adjacent to vesselsCD45RAnaive T-cells++some cell clusters located adjacent to vesselsCD47Lc, Ec, fibroblasts+ to ++some cell clusters located adjacent to vesselsCD49dall Ly++ to +++some cells located adjacent to vesselsCD54Activated Ec, Mo, Ly++ to +++some cells located adjacent to vesselsCD56natural killer cells++many positive cells in proliferative nodules; Ruffine bodies;CD74B-cells++some cells located adjacent to vesselsCD56natural killer cells++many positive cells located adjacent to vesselsCD74B-cells++some cells located adjacent to vesselsCD79bB-cells++to +++foxp3regulatory T-cells++HLA-DP, DQ, DRantigen presenting cells++Mastcell-Tryptasemast cells++S100Dc+++S100Dc+++TCR $\gamma/\delta$ T cells++TCR $\gamma/\delta$	CD25	activated T/B-cells	+ to ++	sporadic positive cells located in proliferative nodules and adjacent to vessels
CD34B lymphoid precursors++ to +++vascular EcsCD44hyaluronan receptor+ to +++cells in proliferative nodules and located adjacent to vesselsCD45RAnaive T-cells++some cell clusters located adjacent to vesselsCD47Lc, Ec, fibroblasts+ to +++sporadic cells located adjacent to vesselsCD49dall Ly++ to +++some cell clusters located adjacent to vesselsCD56natural killer cells++many positive vascular Ecs and cells located in proliferative nodules;CD74B-cells++to +++Sorre cells located adjacent to vesselssome cells located adjacent to vesselsCD56natural killer cells++many positive cells in proliferative nodules; Ruffine bodies;CD74B-cells++to +++Sorre cells located adjacent to vesselsand in proliferative nodulesCD79bB-cells++to +++foxp3regulatory T-cells++HLA-DP, DQ, DRmatigen presenting cells++Mastcell-Tryptasemast cells++S100Dc++TCR $\alpha$ T cells+TCR $\gamma/\delta$ T cells+tCR $\gamma/\delta$ T cells+to ++sporadic cells located adjacent to vesselssorme cells located between fat cells and vessels; many Ruffini bodiesto trypticesome cells located between fat cells and vessels; many Ruffini bodies	CD29	most Lc	+++	many positive cells located in proliferative nodules
CD44hyaluronan receptor+ to +++cells in proliferative nodules and located adjacent to vesselsCD45RAnaive T-cells++some cell clusters located adjacent to vesselsCD45ROactivated T-cells++some cell clusters located adjacent to vesselsCD47Lc, Ec, fibroblasts+ to ++sporadic cells located adjacent to vesselsCD40all Ly++ to (+++)some cell clusters located adjacent to vesselsCD54Activated Ec, Mo, Ly++ to (+++)some positive vascular Ecs and cells located in proliferative nodulesCD56natural killer cells++many positive cells in proliferative nodules; Ruffine bodies;CD74B-cells++ to ++some cells located adjacent to vesselsCD74B-cells+ to ++sporadic to some cells located in proliferative nodulesCD79bB-cells+ to ++sporadic positive cells located in proliferative nodulesfoxp3regulatory T-cells++ to +++sporadic to some positive cells located adjacent to vesselsMastcell-Tryptasemast cells+++sporadic cells located in proliferative nodules and HLAS100Dc+++some cells located between fat cells and vessels; many Ruffini bodiesTCR $\gamma/\delta$ T cells++some cells located adjacent to vessels and focal accumulation	CD34	B lymphoid precursors	++ to <mark>+++</mark>	vascular Ecs
CD45RAnaive T-cells++some cell clusters located adjacent to vesselsCD45ROactivated T-cells++some cell clusters located adjacent to vesselsCD47Lc, Ec, fibroblasts+ to ++sporadic cells located adjacent to vesselsCD49dall Ly++ to +++some cells located adjacent to vesselsCD54Activated Ec, Mo, Ly++ to +++some positive vascular Ecs and cells located in proliferative nodules;CD56natural killer cells++many positive cells in proliferative nodules; Ruffine bodies;CD68Ma+ to ++sporadic to some cells located adjacent to vesselsCD74B-cells+ to ++sporadic to some cells located adjacent to vesselsCD79bB-cells+ to ++sporadic to some positive cells located adjacent to vesselsfoxp3regulatory T-cells+ to ++sporadic to some positive cells located adjacent to vesselsMastcell-Tryptasemast cells++many positive cells located adjacent to vesselsS100Dc+++some cells located between fat cells and vessels; many Ruffini bodiesTCR $\gamma/\delta$ T cells+ to ++some positive cells located adjacent to vessels	CD44	hyaluronan receptor	+ to <mark>+++</mark>	cells in proliferative nodules and located adjacent to vessels
CD45ROactivated T-cells++some cell clusters located adjacent to vesselsCD47Lc, Ec, fibroblasts+ to ++sporadic cells located adjacent to vesselsCD49dall Ly++ to +++some cells located adjacent to vesselsCD54Activated Ec, Mo, Ly++ to +++some cells located adjacent to vesselsCD56natural killer cells++many positive vascular Ecs and cells located in proliferative nodules;CD56natural killer cells++many positive cells in proliferative nodules; Ruffine bodies;CD68Ma+ to ++sporadic to some cells located adjacent to vesselsCD74B-cells+ to ++some cells located adjacent to vessels and in proliferative nodulesCD79bB-cells+ to ++sporadic to some cells located in proliferative nodulesFoxp3regulatory T-cells+ to ++sporadic to some positive cells located adjacent to vesselsMastcell-Tryptasemast cells+++fmany positive cells located adjacent to vesselsS100Dc+++some cells located between fat cells and vessels; many Ruffini bodiesTCR $\alpha$ T cells+some positive cells located adjacent to vessels and focal accumulationTCR $\gamma/\delta$ T cells+ to ++	CD45RA	naive T-cells	++	some cell clusters located adjacent to vessels
CD47Lc, Ec, fibroblasts+ to ++sporadic cells located adjacent to vesselsCD49dall Ly++ to +++some cells located adjacent to vesselsCD54Activated Ec, Mo, Ly++ to +++some positive vascular Ecs and cells located in proliferative nodulesCD56natural killer cells++many positive cells in proliferative nodules; Ruffine bodies; sporadic to some cells located adjacent to vesselsCD56natural killer cells++many positive cells located adjacent to vesselsCD74B-cells+ to ++sporadic to some cells located adjacent to vessels and in proliferative nodulesCD79bB-cells+ to ++sporadic positive cells located in proliferative nodulesfoxp3regulatory T-cells+ to ++sporadic to some positive cells located adjacent to vesselsMastcell-Tryptasemast cells++formation of the top of the	CD45RO	activated T-cells	++	some cell clusters located adjacent to vessels
CD49dall Ly++ to +++some cells located adjacent to vesselsCD54Activated Ec, Mo, Ly++ to +++some positive vascular Ecs and cells located in proliferative nodulesCD56natural killer cells++many positive cells in proliferative nodules; Ruffine bodies; Sporadic to some cells located adjacent to vesselsCD68Ma+ to ++sporadic to some cells located adjacent to vesselsCD74B-cells+ to ++some cells located adjacent to vessels and in proliferative nodulesCD79bB-cells+ to ++sporadic positive cells located in proliferative nodulesfoxp3regulatory T-cells+ to ++sporadic to some positive cells located adjacent to vesselsHLA-DP, DQ, DRantigen presenting cells+++many positive cells located in proliferative nodules and HLA positive endothelial cellsMastcell-Tryptasemast cells+++sporadic cells preferentially located adjacent to vesselsS100Dc+++some cells located between fat cells and vessels; many Ruffini bodiesTCR $\alpha$ T cells+some positive cells located adjacent to vessels and focal accumulationTCR $\gamma/\delta$ T cells++	CD47	Lc, Ec, fibroblasts	+ to ++	sporadic cells located adjacent to vessels
CD54Activated Ec, Mo, Ly++ to +++some positive vascular Ecs and cells located in proliferative nodulesCD56natural killer cells++many positive cells in proliferative nodules; Ruffine bodies; sporadic to some cells located adjacent to vesselsCD68Ma+ to ++sporadic to some cells located adjacent to vesselsCD74B-cells+ to ++some cells located adjacent to vessels and in proliferative nodulesCD79bB-cells+ to ++sporadic positive cells located in proliferative nodulesCD79bB-cells+ to ++sporadic to some positive cells located adjacent to vesselsfoxp3regulatory T-cells+ to ++sporadic to some positive cells located adjacent to vesselsHLA-DP, DQ, DRantigen presenting cells++ to +++many positive cells located in proliferative nodules and HLA positive endothelial cellsMastcell-Tryptasemast cells+++sporadic cells preferentially located adjacent to vesselsS100Dc+++some positive cells located adjacent to vessels and focal accumulationTCR $\alpha$ T cells+some positive cells located adjacent to vessels and focal accumulation	CD49d	all Ly	++ to <mark>+++</mark>	some cells located adjacent to vessels
CD56natural killer cells++many positive cells in proliferative nodules; Ruffine bodies; sporadic to some cells located adjacent to vesselsCD68Ma+ to ++sporadic to some cells located adjacent to vesselsCD74B-cells+ to ++some cells located adjacent to vessels and in proliferative nodulesCD79bB-cells+ to ++sporadic positive cells located in proliferative nodulesfoxp3regulatory T-cells+ to ++sporadic to some positive cells located adjacent to vesselsHLA-DP, DQ, DRantigen presenting cells+ to +++many positive cells located in proliferative nodules and HLA positive endothelial cellsMastcell-Tryptasemast cells+++sporadic cells preferentially located adjacent to vesselsS100Dc+++some cells located between fat cells and vessels; many Ruffini bodiesTCR $\alpha$ T cells+some positive cells located adjacent to vessels and focal accumulationTCR $\gamma/\delta$ T cells+ to ++sporadic cells located perivascular	CD54	Activated Ec, Mo, Ly	++ to <mark>+++</mark>	some positive vascular Ecs and cells located in proliferative nodules
CD68Ma+ to ++sporadic to some cells located adjacent to vesselsCD74B-cells+ to ++some cells located adjacent to vessels and in proliferative nodulesCD79bB-cells+ to ++sporadic positive cells located in proliferative nodulesfoxp3regulatory T-cells+ to ++sporadic to some positive cells located adjacent to vesselsHLA-DP, DQ, DRantigen presenting cells+ to +++many positive cells located in proliferative nodules and HLA positive endothelial cellsMastcell-Tryptasemast cells+++sporadic cells preferentiallly located adjacent to vesselsS100Dc+++some cells located between fat cells and vessels; many Ruffini bodiesTCR $\alpha$ T cells+some positive cells located adjacent to vessels and focal accumulationTCR $\gamma/\delta$ T cells+ to ++sporadic cells located perivascular	CD56	natural killer cells	++	many positive cells in proliferative nodules; Ruffine bodies;
CD74B-cells+ to ++some cells located adjacent to vessels and in proliferative nodulesCD79bB-cells+ to ++sporadic positive cells located in proliferative nodulesfoxp3regulatory T-cells+ to ++sporadic to some positive cells located adjacent to vesselsHLA-DP, DQ, DRantigen presenting cells+ to +++many positive cells located in proliferative nodules and HLA positive endothelial cellsMastcell-Tryptasemast cells+++sporadic cells preferentially located adjacent to vesselsS100Dc+++some cells located between fat cells and vessels; many Ruffini bodiesTCR $\alpha$ T cells+some positive cells located adjacent to vessels and focal accumulationTCR $\gamma/\delta$ T cells+ to ++	CD68	Ma	+ to ++	sporadic to some cells located adjacent to vessels
CD79bB-cells+ to ++sporadic positive cells located in proliferative nodulesfoxp3regulatory T-cells+ to ++sporadic to some positive cells located adjacent to vesselsHLA-DP, DQ, DRantigen presenting cells+ to ++many positive cells located in proliferative nodules and HLAMastcell-Tryptasemast cells+++sporadic cells preferentially located adjacent to vesselsS100Dc+++some cells located between fat cells and vessels; many Ruffini bodiesTCR $\alpha$ T cells+some positive cells located adjacent to vessels and focal accumulationTCR $\gamma/\delta$ T cells+ to ++sporadic cells located perivascular	CD74	B-cells	+ to ++	some cells located adjacent to vessels and in proliferative nodules
foxp3regulatory T-cells+ to ++sporadic to some positive cells located adjacent to vesselsHLA-DP, DQ, DRantigen presenting cells+ to ++sporadic to some positive cells located in proliferative nodules and HLAMastcell-Tryptasemast cells++ to +++sporadic cells preferentially located adjacent to vesselsS100Dc+++some cells located between fat cells and vessels; many Ruffini bodiesTCR $\alpha$ T cells+some positive cells located adjacent to vessels and focal accumulationTCR $\gamma/\delta$ T cells+ to ++sporadic cells located perivascular	CD79b	B-cells	+ to ++	sporadic positive cells located in proliferative nodules
HLA-DP, DQ, DRantigen presenting cells++ to +++many positive cells located in proliferative nodules and HLA positive endothelial cellsMastcell-Tryptasemast cells+++to +++Mastcell-Tryptasemast cells+++S100Dc+++TCR $\alpha$ T cells++TCR $\gamma/\delta$ T cells+ to ++	foxp3	regulatory T-cells	+ to ++	sporadic to some positive cells located adjacent to vessels
Mastcell-Tryptasemast cells+++sporatic cells preferentially located adjacent to vesselsS100Dc+++some cells located between fat cells and vessels; many Ruffini bodiesTCR $\alpha$ T cells+some positive cells located adjacent to vessels and focal accumulationTCR $\gamma/\delta$ T cells+ to ++	HLA-DP, DQ, DR	antigen presenting cells	++ to <mark>+++</mark>	many positive cells located in proliferative nodules and HLA positive endothelial cells
S100Dc+++some cells located between fat cells and vessels; many Ruffini bodiesTCR $\alpha$ T cells+some positive cells located adjacent to vessels and focal accumulationTCR $\gamma/\delta$ T cells+ to ++	Mastcell-Tryptase	mast cells	+++	sporadic cells preferentially located adjacent to vessels
TCR $\alpha$ T cells + some positive cells located adjacent to vessels and focal accumulation TCR $\gamma/\delta$ T cells + to ++ sporadic cells located perivascular	S100	Dc	+++	some cells located between fat cells and vessels' many Ruffini
TCR $\alpha$ T cells + some positive cells located adjacent to vessels and focal accumulation TCR $\gamma/\delta$ T cells + to ++ sporadic cells located perivascular				hodies
TCR $\gamma/\delta$ T cells + to ++ sporadic cells located perivascular	$TCR\alpha$	T cells	+	some positive cells located adjacent to vessels and focal accumulation
	$TCR\gamma/\delta$	T cells	+ to ++	sporadic cells located perivascular

Dc = dendritic cells; Ec = endothelial cells; SMC = smooth muscle cells; Ma = macrophages; Mo = monocytes; MNC = mononuclear cells; Lc = leucocytes; Ly = lymphocytes.

cases, T-cell lines and autologous PBMCs could be cultivated in completely parallel settings (data set for CD4/CD8 ratio calculations).

#### Flow cytometry analysis

The phenotype of the T-cell lines from 33 DD patients was determined by FACS analysis on a FACS Calibur (Becton Dickinson, Franklin Lakes, NJ). Autologous PBMCs served as controls (n = 21). Briefly, fibromatosis-derived T-cell lines and autologous PBMCs were harvested after 21 days of culture and directly labelled using monoclonal antibodies (anti-CD3FITC (1F-202-T100), -CD4PE (1P-359-T100), -CD16FITC (1F-399-T100), -CD25FITC (1F-218-T100), -CD45RA/FITC (1F-223-T100), -CD56PE (1P-231-T100), Exbio, Prague, Czech Republic; -CD8Pe-Cy5.5 (341050), -CD28APC (559770), Becton Dickinson; -CD45RO/APC (17-0457-71), -TCR $\alpha\beta$ /APC (17-9986-71), -TCR $\gamma\delta$ /PE(12-9959-71), -Foxp3/APC (17-4776-71), eBioscience, San Diego, CA).

#### Cytokine analysis

Supernatant analysis for cytokine detection of T-cell lines was performed on samples of 15 different randomly selected Dupuytren's patients using a human Th1/Th2 11plex FlowCytomix Multiplex and a commercial ELISA kit (Bender MedSystems, Vienna, Austria).

#### RNA isolation and TCR CDR3 spectratyping

Total RNA was extracted directly from fibromatous nodules and autologous PBMCs from 15 randomly selected patients (age range = 41-75 years), using TRI reagent (Sigma Aldrich, St. Louis, MO). As previously described by Herndler-Brandstetter et al. [15], TCR V $\beta$  transcripts were amplified by PCR using a Hot-Start Taq Master Mix kit (Qiagen, Vienna, Austria) and primers (MWG Biotech, Ebersberg, Germany) specific for each of the human V $\beta$  families and a specific primer for the constant region of the  $\beta$ -chain (labelled with the fluorochrome 6-FAM). The distribution of clonality was calculated by a standard calculation of percentage.

## **Statistics**

Statistical analysis was performed using Microsoft Excel and SPSS 15.0 software. Wilcoxon W, Kruskal-Wallis, Mann-Whitney U-test, and Fisher's exact test were used to estimate differences between groups and their respective *p*-values.

#### Results

## Evaluation of questionnaires

No significant difference was found between DD patients and healthy controls when compared for the possible presence of autoimmune diseases, allergies, and vascular diseases. A statistically significant number (32.9%) of DD patients in this cohort were smokers, compared to only 18.6% of the control group (p=0.047). However, no correlation was found between smoking habits and stage or recurrence of disease, number of affected finger strings, or number of affected hands.

### Fibromatosis-derived T-cells have a predominantly CD4 + phenotype

Most of the fibromatosis patients had a mixed phenotype, with CD4 + T-cells (median = 80%) prevailing over CD8 + T-cells (median = 22%). The CD4/CD8 ratio, calculated for 15

patients for whom data from fibromatosis T-cells and autologous PBMCs were available, was increased compared to peripheral autologous T-cells (p = 0.07) (Figure 2). Foxp3 + regulatory T-cells were detected in higher numbers in the fibrotic tissue (median = 7%) as compared to peripheral **PBMCs** (median = 2%), and TCR $\alpha\beta$ +T-cells prevailed over TCR $\gamma\delta$  T-cells.

## Fibromatosis-derived T-cells produce mainly $IFN\gamma$ , IL-6, IL-8, and IL-17

DD tissue-derived T-cells from 15 different patients and T-cells expanded from autologous PBMCs were analysed for their cytokine secretion profile (Table 3). Fibromatosis tissuederived T-cells produced similar amounts of the Th1 cytokine IFN $\gamma$  (mean = 3139 pg/ml) as autologous peripheral T-cells (mean = 2908 pg/ml). A significant difference (p < 0.001) in the production of the profibrotic cytokine IL-6 was found between fibromatosis-derived T-cells (mean = 5649 pg/ml) and autologous peripheral mononuclear cells (mean = 105 pg/ml). IL-8, which is mainly produced by macrophages and ECs, but also by T-cells, was secreted to a large extent by T-cells from both sources (T-cells mean = 6859 pg/ml; PBMCs mean = 5956 pg/ml). Moreover, IL-17 secretion turned out to be significantly different (p=0.031) between fibromatosisderived T-cells (mean = 639 pg/ml) and autologous PBMCs (mean = 261 pg/ml).

## Activated endothelium and focal accumulation of mononuclear immune cells

A semiquantitative overview of the immunostaining of sections of Dupuytren's tissue is given in Table 2. Several proinflammatory cytokines were detected in situ, e.g. macrophage migration inhibitory factor (MIF, Figure 3(A); Figure 3(B) represents the negative control rabbit Ig fraction on an adjacent section to 3(A)) and vascular adhesion protein (VAP-1, Figure 3(C)). The profibrotic cytokine  $TGF\beta 1$  was abundantly expressed in the areas containing excessive



Figure 2. T-cells isolated from palmar fibromatosis tissue show an increased CD4/CD8 ratio compared to autologous peripheral bloodderived T-cells (p = 0.076).

Table 3. Cyto	kine expression pr	rofile of fibrom	atosis tissue-	derived (n	= 15) and a	utologous po	eripheral T-cel	ls $(n = 13)$ .						
	Conc. pg/ml	IL-12p70	IFNg	IL-2	IL-10	IL-8	IL-6	IL-4	IL-5	IL-1b	TNF-a	TNF-b	IL-17	TGFb-1
<b>PBMCs</b>	Mean value	1	2 908	417	152	5 956	105	23	402	18	269	63	261	565
	Median	0	1 772	61	59	6 145	82	21	69	1	167	9	74	588
	Min	0	256	0	0	706	0	0	0	0	16	0	6	328
	Max	10	12 633	1657	591	10 629	380	90	3419	82	1255	410	1242	772
Fibromatous	Mean value	2	3 139	90	36	6 859	5 649	21	261	100	118	9	639	640
T-cell	Median	0	1 945	0	17	7 119	5 115	15	14	50	91	0	467	643
	Min	0	0	0	0	4 374	355	0	0	0	4	0	19	347
	Max	32	7 406	156	138	9 290	17 063	75	2581	234	436	47	1242	863
							p > 0.001						p = 0.031	

Note: dupuytren's tissue-derived T-cells secrete mainly IFNY, IL-8, IL-6, IL-17.

Immune cells in Dupuytren's disease 5

extracellular matrix (ECM) molecules (Figure 3(D)), exceeding TNF $\alpha$  (Figure 3(E) and (F)).

Many HLA-DR-positive and S100 protein-positive dendritic cells were found mainly adjoining blood vessels (Figure 3(G) and (H)). Endothelial cells of venules in Dupuytren's tissue also showed a positive staining pattern for HLA-DR.

B-cells and Foxp3-positive regulatory T-cells were scattered within the mononuclear cell infiltrates (Figure 4(A) and (B)). Foxp3 cells reside mostly adjacent to vessels and were found in nodular as well as cord tissue. In sequential sections, CD45RA-positive naïve T-cells were markedly outnumbered by CD45RO-positive activated T-cells (Figure 4(C) and (D)). Numerous partially occluded vessels were dispersed throughout the fibromatosis tissue, accompanied by clusters of naïve and activated T-cells (Figure 4(E) and (F)). Massive expression of the stress protein, heat shock protein 60 (HSP60), was observed too – especially in hyperproliferative nodular areas (Figure 4(H)).

Adjacent autologous aponeurosis tissue, macroscopically unaffected, also turned out to be slightly positive with several of the antibodies applied, e.g. CD8, CD44, CD45RO (Figure 4(G)), CD68, and HLA-DR. Thus, macroscopically "normal" aponeurotic tissue already contained typical cellular inflammatory infiltrations, albeit to a much lower degree.

# T-cells from Dupuytren's nodules have a restricted T-cell repertoire

Figure 5 shows the predominantly oligo-/monoclonally restricted T-cell repertoire of  $\alpha/\beta$  T-cells accumulating in fibromatosis tissue (43%) compared to only 12% of peripheral **T-cells** (p < 0.001). In contrast, peripheral T-cells showed a predominantly polyclonal TCR repertoire (55%), whereas almost no polyclonality was found in fibromatosis nodulesderived T-cells (1%, p < 0.001).

## Discussion

In spite of recent attempts to elucidate the pathogenesis of DD via genome-wide association studies, the precise role of immune mechanisms involved in the development of this disease is not yet understood [16]. DD is characterized by three histological phases: (a) the proliferative phase, characterised by local fibroplasia and the development of nodular lesions with high density of myofibroblasts, followed by (b) the involutional phase, where cells within the nodule realign themselves with the lines of stress in the tissue, and, finally, (c) the residual phase during which nodules disappear leaving relatively acellular, scar-like tissue with an absence of myofibroblasts. Based on our long-standing experience in the study of fibrotic diseases including DD, we believe, that (a) in all forms of fibrosis, inflammatory-immunologic reactions take place in the earliest stages, promoting subsequent profibrotic processes, and (b) elements of both the innate and adaptive immune system are involved in this sequence of events [9].

We detected perivascular clusters of activated T-cells (Figure 4(E) and (F)), mostly positive for TCR receptor  $\alpha\beta$ (TCR $\alpha\beta$ ). Foxp3-positive regulatory T-cells (Figure 4(B)) and B-cells were also present. Meek et al. [17] showed in this context that the inflammatory cells in the nodules - mainly macrophages and lymphocytes - express a common integrin



Figure 3. (A) MIF (macrophage migration inhibitory factor = proinflammatory cytokine) positive fibromatosis tissue (74 years, male; original magnification  $600 \times$ ); (B) Negative control rabbit Ig fraction on an adjacent section to 3(A) (74 years, male; original magnification  $600 \times$ ); (C) VAP-1 (vascular adhesion protein-1) positive vascular endothelium in Dupuytren's tissue (75 years, male; original magnification  $600 \times$ ); (D) Abundant TGF $\beta$ -1 expression in Dupuytren's tissue (72 years, male; original magnification  $100 \times$ ); (E) Blood vessel with exceptionally thick walls showing intense TGF $\beta$ -1 staining in the cytoplasm of DD cord (53 years, male; original magnification  $600 \times$ ); (F) Serial section to area depicted in (E) shows moderate TNF $\alpha$  immunoreactivity in DD cord (53 years, male; original magnification  $600 \times$ ); (G) HLA-DR-positive cells in DD nodule (75 years, male; original magnification  $200 \times$ ); HLA-DR-positive endothelial cells on venules in DD cord (55 years, male; original magnification  $600 \times$ ); (F) Series 2(A–H) immunohistochemical stainings using alkaline-phosphatase and Fast Red for detection were applied.

known as VLA4, which functions as ligand to VCAM-1 present on endothelial cells and the CS1 sequence of fibronectin as well. In contrast to Qureshi et al. [18], we found S100 protein-positive dendritic cells also in DD cord tissue, which provide the local prerequisite for antigenic stimulation of T-cells (Figure 3(H)). Several proinflammatory

cytokines, e.g. MIF (Figure 3(A) and (B) – negative control rabbit Ig fraction), and the key pro-fibrotic cytokine TGF $\beta$ 1 (Figure 3(D)), which lead to recruitment and local proliferation of macrophages, were also detected. Interestingly, immunohistochemistry showed extensive expression of TGF $\beta$ 1 throughout all DD specimens, while cytokine profiling



Figure 4. (A) CD74-positive B cells in cell-dense, actively proliferating DD nodule (62 years, female; original magnification  $200\times$ ); (B) Foxp3-positive regulatory T-cells in palmar fibromatosis tissue (73 years, male; original magnification  $600\times$ ); (C) CD45RA-positive naive T-cells (50 years, male; original magnification  $600\times$ ); (D) Section adjacent to 4(C) stained for CD45RO displays more activated T-cells supporting our FACS data; original magnification  $600\times$ ); (E) Immunofluorescence triple staining of naive CD45+ T cell cluster (Alexa488, green), von Willebrand factor-positive endothelial cells (TRITC, red) and nuclei (DAPI, blue) in Dupuytren's tissue, original magnification  $200\times$ ; (F) Immunofluorescence triple staining of perivascularly CD45RO+activated accumulation of T-cells (Alexa488, green), von Willebrand factor-positive endothelial cells (TRITC, red), and DAPI- (blue) positive nuclei, in DD tissue, original magnification  $600\times$ ; (G) CD45RO + activated T-cells in ''normal'' palmar aponeurosis adjacent to Dupuytren tissue (45 years, male; original magnification  $100\times$ ); (H) HSP60 expression in recurrent Dupuytren's cord (53 years, male; original magnification  $600\times$ ). Peroxidase anti-peroxidas and DAB (diaminobenzidine) were used for detection of HSP60. For (A–D) and (G), immunohistochemical stainings using alkaline-phosphatase and Fast Red for detection were applied.

of fibromatosis tissue-derived T-cells showed, compared to PBMCs, almost identical TGF $\beta$ 1 levels. A possible explanation for this discrepancy is the fact that cytokine analysis was not performed *ex vivo*, but after a series of clonal T-cell expansion lasting 14 days. Th1 cells in DD tissue expressed

IFN $\gamma$ , which locally activates macrophages and induces the expression of MHC class II antigens and acute phase proteins, such as IL-6, which is known to exert profibrotic effects [19]. O'Reilly et al. [20] have shown recently that the profibrotic effect of IL-6 is dependent on STAT3; however, the effect is

indirect and mediated by enhanced TGF- $\beta$  signalling and the classic downstream cellular mediator Smad3. Endothelial cells in Dupuytren's tissue also showed a positive staining for HLA-DR. MHC class II is constitutively expressed in a very restricted number of cell types, such as B-cells and dendritic cells, which are specialised in antigen presentation. However, MHC class II expression can be induced by T-cell derived IFN $\gamma$  in a large variety of other cell types, including endothelial cells [21]. Wick et al. [22] showed HLA-DR positive stainings in atherosclerotic lesions, but not in normal intima, and they hypothesised that this aberrant MHC II expression may participate in the perpetuation of the atherogenic autoimmune reaction. In the present study, endothelial cells of venules with perivascular mononuclear cell infiltration were HLA-DR-positive (Figure 3(G)). Hence, the question arises if T-cells residing in palmar fibromatosis tissue react to pathogenetically relevant antigens. Immunoscope analysis showed that T-cells in DD tissue preferentially display a mono- and oligoclonally-restricted  $\alpha/\beta$  T-cell receptor repertoire compared to autologous peripheral blood (Figure 5). This finding suggests that, in palmar fibromatosis tissue, an expansion of specific T-cell clones takes place, pointing to an antigen-driven mechanism. This is in analogy with the initiation of another fibrotic condition, namely atherosclerosis, where T-cells with a mono- and oligoclonally restricted  $\alpha/\beta$ **T-cell receptor repertoire** play a crucial role. In the latter case, the target antigen for these specific T-cell clones is heat shock protein 60 (HSP60). Several studies provided evidence for increased expression of heat shock proteins, e.g. HSP47 and HSP70, in DD tissue [23]. We additionally found that the stress protein HSP60, a phylogenetically conserved and highly immunogenic molecule, was expressed in hyperproliferative areas of DD nodules at the earliest stage of the disease. Moreover, mononuclear cell infiltrates and ECs were positive for this stress protein, which in our experience represents an important possible candidate for the antigen(s) triggering the local immune response in the palmar tissue of DD patients in response to various stress factors.

Brandes et al. [24] found ECs responding to mechanical stress applied from the outside by producing a remarkable and highly ordered microfilament system, the so-called "stress



Figure 5. Immunoscope analysis shows distribution of TCR V $\beta$  transcripts in intrafibromatosis and autologous peripheral T-cells. A significant monoclonal or oligoclonal restriction of the TCR $\alpha\beta$  repertoire was detected in fibromatosis-derived T-cells, while autologous PBMCs displayed a predominantly polyclonal pattern.

fibres". Murrell et al. [25] hypothesised that narrowing of microvessels may be initiated by genetic factors, ageing, or environmental exposures, leading to localised ischaemia and the generation of free oxygen radicals. A positive feedback mechanism has been proposed: free radicals derived from stressed ECs damage the surrounding tissue and stimulate the proliferation of fibroblasts which excessively synthesise ECM molecules, mainly collagen, leading to further microvascular narrowing, local ischaemia, and oxidative stress. We have evidence in support of Murrell's hypothesis [25], but our focus has been on the role of T-cells as initially triggering factor(s). Thus, we hypothesise that microvascular ECs are functionally impaired by a combination of exogenous and endogenous "stress factors". Functional impairment leads to the attraction and accumulation of T-cells, which react against stressinduced molecules. Subsequently, "innocent by-stander" Tcells and macrophages are attracted, producing further proinflammatory and pro-fibrotic cytokines. The latter mediate the myofibroblast transdifferentiation and uncontrolled production of ECM, leading to the development of full-blown Dupuytren's contracture.

Macroscopically uncompromised aponeurotic tissue, adjacent to Dupuytren tissue, was used for control purposes. Interestingly, we found strong indicators (e.g. activated Tcells, HLA-DR+cells, CD4, CD8, DCs) for a local cellular inflammatory process in this "normal" palmar aponeurotic tissue, most probably representing the earliest steps of the disease process (Figure 4(G)). These sporadically appearing cells were not comparable with DD tissue-infiltrating cells in number, phenotype, or in distribution pattern. However, the presence of inflammatory hallmarks in adjacent "normal" palmar tissue might precede the development of Dupuytren's disease.

The striking accumulation of immune cells, leukocyte adhesion molecules, as well as pro-inflammatory and profibrotic cytokines near markedly narrowed vascular luminae with thickened EC layers strongly supports the theory that the abnormal proliferation of cells in DD is related to immunemediated microvasculature damage. The analysis of fibromatosis-derived T-cells shows a Th1/TH17-weighted immune response. Our findings show a restricted  $\alpha/\beta$ TCR repertoire of intralesional T-cells, which points to an antigen-driven process, although the involved (auto)-antigen(s) have not yet been identified. An (auto)-immune mechanism, similar to that in the development of earliest atherosclerotic vascular changes triggering an immune reaction to (a) altered self molecules and (b) HSPs, might contribute to the development of DD. Thus, it would appear that DD does not occur "spontaneously", but rather is triggered by various endothelial stress factors. The next step in our investigations would be the determination of the antigenic specificity of palmar fibrosisinfiltrating T-cells. HSP60 is an important and plausible candidate in this context.

Mechanical stress, possibly combined with other stress factors (alcohol, smoking, etc) leads to local immune reactions against autoantigens, reflected by the restriced T-cell-receptor repertoire. These stressors induce simultaneous expression of adhesion molecules and HSP 60 or other stress proteins in the palmar aponeurosis. Mechanically induced vascular damage represents an additional stress factor, leading to increased permeability, extravasation of inflammatory cells, and hypoxic condition.

## Acknowledgements

The authors acknowledge the Lore-and-Udo-Saldow Donation, the Competence Centre Medicine Tyrol, and the Medizinischer Forschungsfonds Tirol for supporting the project.

We thank Sandra Hussl, Christoph Grabmer, Brigitte Jenewein, Andrea Eigentler, Michael Keller, Daniela Niederwieser, Ruth Pfeilschifter, and Harald Niederegger for technical support, and Dr Bettina Zelger for help with Dupuytren's sample staging. Thanks also to Dr Ling Toh, Dr Otto Majdic, and Dr E. Liehl for supplying antibodies and recombinant IL-2. Dr Hanno Ulmer and Dr Richard Pfaringer supported the statistical evaluation of data.

**Declaration of interest:** The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper.

### References

- Wilbrand S, Flodmark C, Ekbom A, Gerdin B. Activation markers of connective tissue in Dupuytren's contracture: relation to postoperative outcome. Scand J Plast Reconstr Surg Hand Surg 2003;37:283–92.
- [2] Mickelson DT, Noland SS, Watt AJ, et al. Prospective randomized controlled trial comparing 1- versus 7-day manipulation following collagenase injection for Dupuytren contracture. J Hand Surg Am 2014;39:1933–41.
- [3] Shih B, Bayat A. Scientific understanding and clinical management of Dupuytren disease. Nat Rev Rheumatology 2010;6:715–26.
- [4] Dolmans GH, Werker PM, Hennies HC, et al. Wnt Signaling and Dupuytren's disease. N Engl J Med 2011;365:307–17.
- [5] Kischer CW, Speer DP. Microvascular changes in Dupuytren's contracture. J Hand Surg Am 1984;9A:58–62.
- [6] Burke FD, Proud G, Lawson IJ, et al. An assessment of the effects of exposure to vibration, smoking, alcohol and diabetes on the prevalence of Dupuytren's disease in 97,537 miners. J Hand Surg Eur 2007;32:400–6.
- [7] Murrell GAC, Francis M, Bromley L. Free radicals and Dupuytren's contracture. Br Med J 1987;295:1373–5.
- [8] Wick G, Backovic A, Rabensteiner E, et al. The immunology of fibrosis: innate and adaptive responses. Trends Immunol 2010;31:110–19.
- [9] Wick G, Grundtman C, Mayerl C, et al. The immunology of fibrosis. Annu Rev Immunol 2013;31:107–35.

- [10] Andrew JG, Andrew SM, Ash A, Turner B. An investigation into the role of inflammatory cells in Dupuytren's disease. J Hand Surg Br 1991;16:237–9.
- [11] Gudmundsson KG, Arngrímsson R, Arinbjarnarson S. Tand B-lymphocyte subsets in patients with Dupuytren's disease. Correlations with disease severity. J Hand Surg Br 1998;23:724–7.
- [12] Baird KS, Alwan WH, Crossan JF, Wojciak B. Tcell-mediated response in Dupuytren's disease. Lancet 1993;342:366
- [13] Wolfram D, Rabensteiner E, Grundtman C, et al. T regulatory cells and TH17 cells in peri-silicone implant capsular fibrosis. Plast Reconstr Surg 2012;129:327e–37.
- [14] Rehman S, Salway F, Stanley JK, et al. Molecular phenotypic descriptors of Dupuytren's disease defined using informatics analysis of the transcriptome. J Hand Surg Am 2008;33: 359–72.
- [15] Herndler-Brandstetter D, Schwaiger S, Veel E, et al. CD25expressing CD8+ T cells are potent memory cells in old age. J Immunol 2005;175:1566–74.
- [16] Lee LC, Zhang AY, Chong AK, et al. Expression of a novel gene, MafB, in Dupuytren's disease. J Hand Surg 2006;31A:211–18.
- [17] Meek RM, McLellan S, Crossan JF. Dupuytren's disease. A model for the mechanism of fibrosis and its modulation by steroids. J Bone Joint Surg Br. 1999;81(4):732–8. Erratum in: J Bone Joint Surg Br 1999;81(5):938.
- [18] Qureshi FI, Hornigold R, Spencer JD, Hall SM. Langerhans cells in Dupuytren's contracture. J Hand Surg Br 2001;26: 362–7.
- [19] Ma F, Li Y, Jia L, et al. Macrophage-stimulated cardiac fibroblast production of IL-6 is essential for TGF  $\beta$ /Smad activation and cardiac fibrosis induced by angiotensin II. PLoS One 2009;7:e35144.
- [20] O'Reilly S, Ciechomska M, Cant R, van Laar JM. Interleukin-6 (IL-6) trans signaling drives a STAT3-dependent pathway that leads to hyperactive transforming growth factor- $\beta$  (TGF- $\beta$ ) signaling promoting SMAD3 activation and fibrosis via Gremlin protein. J Biol Chem 2014;289: 9952–60.
- [21] Boehm U, Klamp T, Groot M, Howard JC. Cellular responses to interferon-gamma. Annu Rev Immunol 1997;15: 749–95.
- [22] Wick G, Knoflach M, Xu Q. Autoimmune and inflammatory mechanisms in atherosclerosis. Annu Rev Immunol 2004;22:361–403.
- [23] Kraljevic Pavelic S, Sedic M, Hock K, et al. An integrated proteomics approach for studying the molecular pathogenesis of Dupuytren's disease. J Pathol 2009;217:524–33.
- [24] Brandes G, Reale E, Messina A. Microfilament system in the microvascular endothelium of the palmar fascia affected by mechanical stress applied from outside. Virchows Arch 1996;429:165–72.
- [25] Murrell GA, Francis MJ, Bromley L. Modulation of fibroblast proliferation by oxygen free radicals. Biochem J 1990;265:659–65.